Faulk Kelly E, Kairalla John A, Dreyer ZoAnn E, Carroll Andrew J, Heerema Nyla A, Devidas Meenakshi, Carroll William L, Raetz Elizabeth A, Loh Mignon L, Hunger Stephen P, Borowitz Michael, Wang Cindy, Guest Erin, Brown Patrick A
Pediatric Oncology, University of Colorado Anschutz Medical Campus, Denver, Colorado, USA.
Biostatistics, University of Florida, Gainesville, Florida, USA.
Pediatr Blood Cancer. 2023 May 31:e30467. doi: 10.1002/pbc.30467.
We measured minimal residual disease (MRD) by multiparameter flow cytometry at three time points (TP) in 117 infants with KMT2A (lysine [K]-specific methyltransferase 2A)-rearranged and 58 with KMT2A-germline acute lymphoblastic leukemia (ALL) on Children's Oncology Group AALL0631 study. For KMT2A-rearranged patients, 3-year event-free survival (EFS) by MRD-positive (≥0.01%) versus MRD-negative (<0.01%) was: TP1: 25% (±6%) versus 49% (±7%; p = .0009); TP2: 21% (±8%) versus 47% (±7%; p < .0001); and TP3: 22% (±14%) versus 51% (±6%; p = .0178). For KMT2A-germline patients, 3-year EFS was: TP1: 88% (±12%) versus 87% (±5%; p = .73); TP2: 100% versus 88% (±5%; p = .24); and TP3: 100% versus 87% (±5%; p = .53). MRD was a strong independent outcome predictor in KMT2A-rearranged, but not KMT2A-germline infant ALL.
在儿童肿瘤学组AALL0631研究中，我们通过多参数流式细胞术在三个时间点（TP）对117例KMT2A（赖氨酸[K]特异性甲基转移酶2A）重排的婴儿和58例KMT2A种系急性淋巴细胞白血病（ALL）患儿进行了微小残留病（MRD）检测。对于KMT2A重排的患者，MRD阳性（≥0.01%）与MRD阴性（<0.01%）的3年无事件生存率（EFS）分别为：TP1：25%（±6%）对49%（±7%；p = 0.0009）；TP2：21%（±8%）对47%（±7%；p < 0.0001）；TP3：22%（±14%）对51%（±6%；p = 0.0178）。对于KMT2A种系患者，3年EFS分别为：TP1：88%（±12%）对87%（±5%；p = 0.73）；TP2：100%对88%（±5%；p = 0.24）；TP3：100%对87%（±5%；p = 0.53）。MRD是KMT2A重排婴儿ALL的一个强有力的独立预后预测指标，但在KMT2A种系婴儿ALL中并非如此。
